Fat‑targeted treatment with pioglitazone or tirzepatide for normal‑weight type 2 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study compares three groups—normal‑weight people with type 2 diabetes, overweight people with type 2 diabetes, and normal‑weight people without diabetes—to define differences in fat cell function and fat distribution. Participants will undergo metabolic testing including OGTT and insulin resistance measures, body composition by DXA and MRI, and fat biopsies to analyze adipocyte biology. Individuals with normal‑weight diabetes will be treated with adipocyte‑directed therapies (pioglitazone or tirzepatide) and followed for changes in insulin sensitivity, fat distribution, and metabolic biomarkers. The goal is to link biological mechanisms in fat tissue to clinical metabolic outcomes and identify whether these therapies improve metabolic health in normal‑weight diabetes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Normal-Weight Diabetes (NWD) Group:

1. Age: 30 to 70 years old.
2. Diagnosis of Type 2 Diabetes (T2D): Based on a previous diagnosis or confirmed by laboratory testing at screening (A1c \> 5.7% or fasting glucose \> 100 mg/dL).
3. HbA1c Range: Between 5.7% and 8%, with a stable medication or lifestyle regimen for at least 3 months.
4. BMI: Between 19 and 24.9 kg/m².
5. Diabetes Medications: All diabetes medications are allowed, except insulin and pioglitazone. GLP-1 receptor agonists are permitted if the dose has been stable for 3 months.
6. Stable Body Weight: Body weight must have been stable (no more than 2 kg change) over the last 3 months.

Normal-Weight Control (NWC) Group:

1. Age: 30 to 70 years old.
2. No Diagnosis of Diabetes: Fasting plasma glucose \< 100 mg/dL and A1c \< 5.7%, with no history of glucose-lowering medications.
3. BMI: Between 19 and 24.9 kg/m².
4. Stable Body Weight: No more than 2 kg change over the past 3 months. -

Exclusion Criteria:

1. Pregnancy or Lactation: Women who are pregnant, planning to become pregnant, or breastfeeding are excluded due to potential risks to the fetus or infant.
2. Prior Use of Pioglitazone: Participants who have previously used pioglitazone are excluded to avoid confounding effects of prior drug exposure.
3. Unstable Body Weight: Individuals with a body weight change of more than 2 kg in the last 3 months are excluded to ensure stable metabolic conditions.
4. Liver or Kidney Disease: Participants with significant liver disease (ALT \> 3x upper limit of normal) or renal disease (creatinine \> 1.5 mg/dL) are excluded due to potential safety risks.
5. Congestive Heart Failure or Fluid Overload History: These conditions are exclusionary due to the risk of fluid retention with pioglitazone.
6. Uncontrolled Hypertension: Blood pressure \> 160/90 mmHg excludes participants due to increased cardiovascular risk.
7. Active Cancer: Individuals with a diagnosis of cancer in the past 3 years (except for skin cancer) are excluded.
8. Chronic Inflammatory Diseases: Excluded due to potential effects on metabolic measurements.
9. Use of Weight Loss Medications: Those currently taking weight loss medications are excluded to prevent confounding effects on body weight and metabolic function.
10. Bariatric Surgery or Liposuction History: Participants who have had weight-loss surgeries or liposuction are excluded due to alterations in fat tissue and metabolic profiles.
11. Insulin Use: Participants using insulin are excluded to focus on non-insulin-dependent diabetes.
12. Active Psychiatric Disease or Eating Disorders: Individuals with these conditions are excluded due to potential impacts on study compliance and data integrity.
13. Substance Abuse: Participants with a history of substance abuse are excluded for similar reasons.

    \-

Where it's running

• Stanford University
  Palo Alto, California, United States Recruiting
• Stanford University, Clinical and Translational Research Unit (CTRU)
  Stanford, California, United States Not yet recruiting

Study contacts

• Study coordinator: Nina Shenoy, BS
• Email: nshenoy8@stanford.edu
• Phone: 408-896-0134

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cognitive screening and multidomain care to slow memory and thinking decline in older adults with type 2 diabetes

  This study will test whether regular cognitive screening plus a two-year program of medication optimization, adjusted HbA1c targets, vascular risk management, lifestyle changes, and social support can slow cognitive decline in people aged 65 and older with type 2 diabetes.

  Recruiting at 3 sites Steno Diabetes Center Copenhagen · Copenhagen and 2 other locations · NCT07250789

• iLet Bionic Pancreas started through primary care for adults on insulin

  This project will test whether starting the iLet Bionic Pancreas through primary care helps adults with insulin-treated type 1 or type 2 diabetes lower their A1c more than routine care over 13 weeks.

  Recruiting University of Colorado, Denver · Aurora, Colorado and 1 other locations · NCT07011147

• AI-guided microbiome nutrition to help manage blood sugar in type 2 diabetes

  A fixed, microbiome-targeted nutritional product is being tested to see if it lowers HbA1c in adults with type 2 diabetes when added to their usual diabetes care.

  Recruiting Enbiosis Biotechnologies · Izmir · NCT07622628

• ROME GS sensor comparison with Eversense 365 for continuous glucose monitoring

  This study will test whether the redesigned ROME GS glucose sensor is as safe and accurate as the Eversense 365 in adults with diabetes.

  Recruiting at 3 sites Senseonics, Inc. · Escondido, California and 3 other locations · NCT07518004

• Family Good Health Traditions for Life program

  This program will try a community-tailored, family-based version of the Diabetes Prevention Program to help Black parents with prediabetes and their children lower weight and reduce diabetes risk.

  Recruiting Morehouse School of Medicine · Albany, Georgia · NCT07441655

• Semaglutide's effects on heart and muscle mass

  This project will use MRI scans and strength tests over 12 months to see if semaglutide changes body and heart muscle in adults starting the medication.

  Recruiting University of Alberta · Edmonton, Alberta · NCT07272837

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.